Role of HDL as strong, independent risk factor & role of Nicotinic as a broad lipid regulator.

HDL is strong risk factor and recommended for risk estimation (Class 1 recommendation).

HDL can contribute to substantial risk estimation as a separate variable (HeartScore Risk calculator)

LDL HDL & TGs have class 1 recommendation to be analyzed before initiation of treatment.

Aggressive LDL lowering in very high risk patients ( less than 70 mg/dl and/or 50% LDL reduction)

Very High risk patients:

1) Established CVD 2) Type 2 diabetes 3) Type 1 diabetes 4)Moderate to severe CKD

Nicotinic Acid recommended for LDL-lowering after highest tolerable dose of Statin

Level A evidence for Nicotinic Acid for treating low HDL-C

Level A evidence for Statin + Nicotinic Acid of evidence to reduce HTG.

Statin + Nicotonic acid is the first line recommendation for Mixed Dyslipidemia

Aggressive treatment of LDL & non-HDL-C (TCHDL)

Stroke
Nicotinic Acid alone or in combination with Statins may further benefit in stroke prevention. It clearly shows large evidences in support of Nicotinic Acid for Stroke reduction.

Other Benefits
90% reduction in CV events (HATS) Niacin + Statins Plaque regression CIMT reduction

Low HDL-C is associated with excess events and mortality even in CAD patients even when LDL-C lower than 70 mg/dl. Low levels of HDL constitute a strong, independent & inverse predictor of the risk of premature development of atherosclerosis & CVD.

Tredaptive Consistent efficacy on all Lipid Parameters

Reduction of atherogenic lipid parameters LDL-> 15-18 % TG -> 20-40 % Non-HDL-C-> 20% Lp A -> 30 % (Only effective lipid regulator) Apo B -> 20% Increase of Atheroprotective parameters HDL 25 %

Tredaptive : Ideal lipid modulator